



ANRS | MIE Scientific Days in Vietnam

Towards ending epidemics

15th to 16th of November, 2023

Dengue control: Status quo, challenges and Prospects

DO Kien Quoc, MPH

Institute Pasteur in Ho Chi Minh City, Vietnam



Contents




- Dengue burden
- Dengue response
- Challenges
- Prospects
- Solutions


Dengue burden



Number of People Killed by Animals per Year



Ten Threats to Global Health in 2019



390mn
annual dengue virus infections globally



3.9bn
people are at risk of dengue infections


Dengue cases reported to WHO rose over 8-fold in last 20 years

Deaths due to dengue up from 960 in 2000 to 4,032 in 2015

Dengue is now endemic in more than 100 countries



Dengue cases (million)



Risk of infection in 129 countries

Most dengue cases reported in 2019

Source: WHO estimates | Graphic: Somrat Sharma, Sarfaraz



DENGUE IN ASIA THE NUMBER STORY

ASIA

IS THE MOST IMPACTED REGION WITH ABOUT **75%** OF THE GLOBAL BURDEN OF **DENGUE**



HOTSPOTS IN ASIA


PHILIPPINES 166,107 CASES
THAILAND 150,454 CASES
INDONESIA 101,218 CASES
VIETNAM 66,140 CASES
MALAYSIA 43,346 CASES
SINGAPORE 22,205 CASES



Dengue burden



Dengue infection and fatality in Vietnam during 1980 - 2023




Source: General Department of Preventive Medicine – Ministry of Health


Dengue burden



Số mắc sốt xuất huyết nhập viện và số tử vong theo tuần năm 2023 so với năm 2022




Dengue in the South from 2020 to 9/2023




Regions	Cumulative to W42/2023		Cumulative to W42/2022	Cases discrepancy (%)
	Cases	Cases / 100,000 person		
North	37306	90.0	17669	111.1
Centre	18686	152.6	50581	-63.1
Highland	10204	239.5	18895	-46.0
South	55168	127.4	188476	-70.7
Nation	121364	119.9	275621	56

Dengue incidence and sero-types from 1996




Source: General Department of Preventive Medicine – Ministry of Health

Source: Pasteur Institute in Ho Chi Minh City, Vietnam






“Surveillance for action”







Challenges



Source: NASA, *Of Mosquitoes and Models: Tracking Disease by Satellite*, *Of Mosquitoes and Models: Tracking Disease by Satellite* (nasa.gov)



Source: Jane Messina, Oliver J Brady et al, The current and future global distribution and population at risk of dengue, *Nature Microbiology* 4(9):1-8, DOI:[10.1038/s41564-019-0476-8](https://doi.org/10.1038/s41564-019-0476-8)



Note: Data refer to cases reported in the last 12 months. Administrative boundaries: © Eurographics. The boundaries and names shown on this map do not imply official endorsement or acceptance by the European Union. ECDC. Map produced on 19 January 2023

nature

Explore content ▾ About the journal ▾ Publish with us ▾ Subscribe

nature > news explainer > article

NEWS EXPLAINER | 31 October 2023

Dengue is spreading in Europe: how worried should we be?

The post-COVID travel boom combined with a warm summer have led to dengue outbreaks in Italy and France.

Warming Temperatures To Spike Dengue In US, Europe: WHO Scientist

Date 17/7/2023 9:15:15 AM


Share on Facebook Tweet on Twitter

(MENAFN- IANS) London, Nov 7 (IANS) Increasing climate change is expected to drive dengue, a mosquito-borne disease that kills thousands of people every year, to newer areas like the US and Europe, warned a scientist at the World Health Organization (WHO) calling health authorities to start preparing to combat the disease.

Challenges



Challenges



Am J Trop Med Hyg. 1988 Jan;38(1):172-80.

A prospective study of dengue infections in Bangkok.

Burke DS¹, Nisalak A, Johnson DE, Scott RM.

Abstract

Dengue infections were prospectively studied among 4- to 16-year-old students at a Bangkok school. Blood samples were obtained from 1,757 students in June 1980, before the dengue season, and in January 1981, after the season, and tested for dengue antibodies by the hemagglutination inhibition method. Classrooms were monitored daily for school absences. Fifty percent of the children had antibodies to, and were presumably immune to, at least 1 dengue serotype by the age of 7 years. Most (90/103, 87%) students who became infected by dengue viruses during the study period were either asymptomatic or minimally symptomatic (absent only 1 day). Most (7/13, 53%) of the symptomatic dengue infections (absent with fever for greater than or equal to 2 days) were clinically recognized as cases of dengue hemorrhagic fever which required hospitalization. None of 47 primary dengue infections required hospitalization, whereas 7 of 56 secondary infections did ($P = 0.012$). Preexistent dengue immunity, as detected by conventional serologic techniques, was a significant (odds ratio greater than or equal to 6.5) risk factor for development of dengue hemorrhagic fever.

Epidemiol. Infect. (2012), 140, 491–499. © Cambridge University Press 2011
doi:10.1017/S0950268811001191

Under-recognition and reporting of dengue in Cambodia: a capture–recapture analysis of the National Dengue Surveillance System

S. VONG^{1*}, S. GOYET¹, S. LY¹, C. NGAN², R. HUY², V. DUONG¹, O. WICHMANN³, G. W. LETSON³, H. S. MARGOLIS³ AND P. BUCHY¹

¹ Institut Pasteur in Cambodia, Réseau International des Instituts Pasteur, Phnom Penh, Cambodia

² National Dengue Control Programme, Ministry of Health, Phnom Penh, Cambodia

³ Pediatric Dengue Vaccine Initiative, International Vaccine Institute, Seoul, Korea

the annual incidence ranged from 13.4 to 57.8/1000 person-seasons. During the same period, NDSS incidence rates ranged from 1.1/1000 to 5.7/1000, which was 3.9- to 29.0-fold lower than found in the capture–recapture study. In hospitalized cases, the rate of under-recognition was 1.1- to 2.4-fold. This study shows the substantial degree of under-recognition/reporting of dengue and that reported hospitalized cases are not a good surrogate for estimating dengue disease burden.

Asymptomatic humans transmit dengue virus to mosquitoes


Veasna Duong,^{a,1} Louis Lambrechts,^{b,c,1} Richard E. Paul,^{c,d} Sowath Ly,^e Rath Srey Lay,^a Kanya C. Long,^f Rekol Huy,^g Arnaud Tarantola,^e Thomas W. Scott,^{f,h} Anavaj Sakuntabhai,^{c,d} and Philippe Buchy^{a,i,2}

Moreover, at a given level of viremia, DENV-infected people with no detectable symptoms or before the onset of symptoms are significantly more infectious to mosquitoes than people with symptomatic infections. Because DENV viremic people without clinical symptoms may be exposed to more mosquitoes


Challenges



Intervention implemented when infections are lowest (Apr-May)




Intervention implemented when infections are highest (Sep-Oct)




Unpublished data by US.CDC, Dengue unit, Puerto Rico

Challenges



Source: Newton, E. and Reiter, P. (1992), *Am. J. Trop. Med. Hyg.*, 47(6), 1992, pp. 709-720



Source: Reiter, P. and Newton, E. (1992), *Dengue, a Worldwide Problem, a Common Strategy*, MoH, Mexico City



Models

- EWARDS (WHO-TDR): logistics regression
- D-MOSS (UK) & E-DENGUE (Australia): synthesis of many mathematical models (Mathematical ensembles)




Input parameters:

- EWARDS: monthly cases, hydrometeorology
- D-MOSS: monthly disease cases and hydro-meteorological forecast
- E-DENGUE: monthly cases, hydrometeorology, socio-economics and intervention activities

Predictability:

- Forecast time window: from 1 week to 6 months (D-MOSS: 6 months in advance, E-DENGUE: 2 months in advance, EWARDS: 1 to 12 weeks in advance)
- Forecast level: depends on the tool (D-MOSS to province, E-DENGUE to districts and possibly communes)




Utilities: kit (EWARDS), web (D-MOSS), web + mobile app (E-DENGUE)



Prospects



- Wolbachia is a natural bacteria
- To be transmitted from mosquitoes to their offsprings via eggs
- Safety for human, animals, and environment
- To reduce disease transmission by mosquitoes (Dengue, Zika, Chikungunya)



Source: World Mosquito Program-WMP




There exists consistent global evidence of a reduction in the incidence of dengue following the implementation of the release of wMel-carrying mosquitoes



Source: World Mosquito Program-WMP


Estimates of the effect of WMP's *Wolbachia* method on dengue incidence



* Yogyakarta data post-September 2020 excluded as releases in the control area commenced in Oct 2020



There are many vaccines against dengue that are being researched and developed



*Based on current vaccine landscape (02/2023)



	CYD-TDV	TAK-003
Ages	9-45 years old <i>(Required serological testing before vaccination)</i>	≥ 4 years old <i>(non-required serological testing before vaccination)</i>
Dose	3 doses (0, 6, 12 month)	2 doses (0, 3 month)
VE against VCD (virologically confirmed dengue)	65,6% (60,7-69,9)	62% (56,6-66,7)
VE against hospitalization VCD	80,8% (70,1-87,7)	83,6% (76,8-88,4)

Source:


Hadinegoro SR, *N Engl J Med* 2015; 373:1195-1206;

Rivera L, *Clin Infect Dis*, 2022 Aug 24;75(1):107-117

Solutions



- Toward to the future by new prevention tool with more efficacy
 - Vaccine
 - Vector control:
 - Mosquito carry *Wolbachia*
 - **Genetically** modified mosquito



Thank you!





ANRS | MIE Scientific Days in Vietnam

Towards ending epidemics

15th to 16th of November, 2023

Phòng chống sốt xuất huyết: Thực trạng, thách thức và Triển vọng

DO Kien Quoc, MPH

Institute Pasteur in Ho Chi Minh City, Vietnam






- Gánh nặng của sốt xuất huyết
- Ứng phó với sốt xuất huyết
- Thách thức
- Tương lai
- Các giải pháp


Gánh nặng của sốt xuất huyết



Number of People Killed by Animals per Year



Ten Threats to Global Health in 2019



390mn annual dengue virus infections globally

3.9bn people are at risk of dengue infections

Risk of infection in 129 countries

Most dengue cases reported in 2019

Dengue cases reported to WHO rose over 8-fold in last 20 years

Deaths due to dengue up from 960 in 2000 to 4,032 in 2015

Dengue is now endemic in more than 100 countries

Dengue cases (million)

Year	Dengue cases (million)
2000	0.5
2010	2.4
2019	5.2

Source: WHO estimates | Graphic: Somrat Sharma, Sarfaraz

DENGUE IN ASIA THE NUMBER STORY

ASIA
IS THE MOST IMPACTED REGION WITH ABOUT **75%** OF THE GLOBAL BURDEN OF **DENGUE**

HOTSPOTS IN ASIA


- PHILIPPINES 166,107 CASES
- THAILAND 150,454 CASES
- INDONESIA 101,218 CASES
- VIETNAM 66,140 CASES
- MALAYSIA 43,346 CASES
- SINGAPORE 22,205 CASES



Gánh nặng của sốt xuất huyết



Số các sốt xuất huyết và tử vong ở Việt Nam trong giai đoạn 1980 - 2023




Nguồn: Cục Y tế dự phòng – Bộ Y tế


Gánh nặng của sốt xuất huyết



Số mắc sốt xuất huyết nhập viện và số tử vong theo tuần năm 2023 so với năm 2022




Dengue in the South from 2020 to 9/2023




Regions	Cumulative to W42/2023		Cumulative to W42/2022	Cases discrepancy (%)
	Cases	Cases / 100,000 person		
North	37306	90.0	17669	111.1
Centre	18686	152.6	50581	-63.1
Highland	10204	239.5	18895	-46.0
South	55168	127.4	188476	-70.7
Nation	121364	119.9	275621	56

Dengue incidence and sero-types from 1996



Source: General Department of Preventive Medicine – Ministry of Health

Source: Pasteur Institute in Ho Chi Minh City, Vietnam



Phòng ngừa liên tục


Can thiệp vào ổ dịch

Giảm nguồn lây nhiễm

Can thiệp dịch bệnh




“Giám sát để hành động”






Thách thức



Source: NASA, *Of Mosquitoes and Models: Tracking Disease by Satellite*, *Of Mosquitoes and Models: Tracking Disease by Satellite* (nasa.gov)



Source: Jane Messina, Oliver J Brady et al, The current and future global distribution and population at risk of dengue, *Nature Microbiology* 4(9):1-8, DOI:[10.1038/s41564-019-0476-8](https://doi.org/10.1038/s41564-019-0476-8)

nature

Explore content ▾ About the journal ▾ Publish with us ▾ Subscribe

nature > news explainer > article

NEWS EXPLAINER | 31 October 2023

Dengue is spreading in Europe: how worried should we be?


The post-COVID travel boom combined with a warm summer have led to dengue outbreaks in Italy and France.

Warming Temperatures To Spike Dengue In US, Europe: WHO Scientist

Date 17/7/2023 9:15:15 AM

Share on Facebook Tweet on Twitter

(MENAFN- IANS) London, Nov 7 (IANS) Increasing climate change is expected to drive dengue, a mosquito-borne disease that kills thousands of people every year, to newer areas like the US and Europe, warned a scientist at the World Health Organization (WHO) calling health authorities to start preparing to combat the disease.




Note: Data refer to cases reported in the last 12 months. Administrative boundaries: © Eurographics. The boundaries and names shown on this map do not imply official endorsement or acceptance by the European Union. ECDC. Map produced on 19 January 2023

Thách thức



Thách thức



Am J Trop Med Hyg. 1988 Jan;38(1):172-80.

A prospective study of dengue infections in Bangkok.

Burke DS¹, Nisalak A, Johnson DE, Scott RM.

Abstract

Dengue infections were prospectively studied among 4- to 16-year-old students at a Bangkok school. Blood samples were obtained from 1,757 students in June 1980, before the dengue season, and in January 1981, after the season, and tested for dengue antibodies by the hemagglutination inhibition method. Classrooms were monitored daily for school absences. Fifty percent of the children had antibodies to, and were presumably immune to, at least 1 dengue serotype by the age of 7 years. **Most (90/103, 87%) students who became infected by dengue viruses during the study period were either asymptomatic or minimally symptomatic (absent only 1 day).** Most (7/13, 53%) of the symptomatic dengue infections (absent with fever for greater than or equal to 2 days) were clinically recognized as cases of dengue hemorrhagic fever which required hospitalization. None of 47 primary dengue infections required hospitalization, whereas 7 of 56 secondary infections did ($P = 0.012$). Preexistent dengue immunity, as detected by conventional serologic techniques, was a significant (odds ratio greater than or equal to 6.5) risk factor for development of dengue hemorrhagic fever.

Epidemiol. Infect. (2012), **140**, 491–499. © Cambridge University Press 2011
doi:10.1017/S0950268811001191

Under-recognition and reporting of dengue in Cambodia: a capture–recapture analysis of the National Dengue Surveillance System

S. VONG^{1*}, S. GOYET¹, S. LY¹, C. NGAN², R. HUY², V. DUONG¹, O. WICHMANN³, G. W. LETSON³, H. S. MARGOLIS³ AND P. BUCHY¹

¹ Institut Pasteur in Cambodia, Réseau International des Instituts Pasteur, Phnom Penh, Cambodia

² National Dengue Control Programme, Ministry of Health, Phnom Penh, Cambodia

³ Pediatric Dengue Vaccine Initiative, International Vaccine Institute, Seoul, Korea

the annual incidence ranged from 13.4 to 57.8/1000 person-seasons. During the same period, NDSS incidence rates ranged from 1.1/1000 to 5.7/1000, which was 3.9- to 29.0-fold lower than found in the capture–recapture study. **In hospitalized cases, the rate of under-recognition was 1.1- to 2.4-fold.** This study shows the substantial degree of under-recognition/reporting of dengue and that reported hospitalized cases are not a good surrogate for estimating dengue disease burden.

Asymptomatic humans transmit dengue virus to mosquitoes


[Veasna Duong](#),^{a,1} [Louis Lambrechts](#),^{b,c,1} [Richard E. Paul](#),^{c,d} [Sowath Ly](#),^e [Rath Srey Lay](#),^a [Kanya C. Long](#),^f [Rekol Huy](#),^g [Arnaud Tarantola](#),^e [Thomas W. Scott](#),^{f,h} [Anavaj Sakuntabhai](#),^{c,d} and [Philippe Buchy](#)^{a,i,2}

Moreover, at a given level of viremia, **DENV-infected people with no detectable symptoms or before the onset of symptoms are significantly more infectious to mosquitoes than people with symptomatic infections.** Because DENV viremic people without clinical symptoms may be exposed to more mosquitoes


Thách thức




Intervention implemented when infections are lowest (Apr-May)




Intervention implemented when infections are highest (Sep-Oct)



Dữ liệu chưa được công bố của US.CDC, đơn vị sốt xuất huyết, Puerto Rico



Source: Newton, E. and Reiter, P. (1992), *Am. J. Trop. Med. Hyg.*, 47(6), 1992, pp. 709-720



Source: Reiter, P. and Newton, E. (1992), *Dengue, a Worldwide Problem, a Common Strategy*, MoH, Mexico City

Triển vọng



❑ Mô hình

- ❑ **EWARDS (WHO-TDR):** logistics regression
- ❑ **D-MOSS (UK) & E-DENGUE (Australia):** tổng hợp nhiều mô hình toán học (Mathematical ensembles)




❑ Thông số đầu vào:

- ❑ **EWARDS:** các ca hàng tháng, khí tượng thủy văn
- ❑ **D-MOSS:** các ca bệnh hàng tháng và dự báo khí tượng thủy văn
- ❑ **E-DENGUE:** các ca bệnh hàng tháng, khí tượng thủy văn, kinh tế - xã hội và các hoạt động can thiệp

❑ Khả năng dự đoán:




- ❑ **Khoảng thời gian dự báo:** từ 1 tuần đến 6 tháng (D-MOSS: trước 6 tháng, E-DENGUE trước 2 tháng, EWARDS: trước 1 đến 12 tuần)
- ❑ **Mức độ dự báo:** tùy theo công cụ (D-MOSS cho tỉnh, E-DENGUE cho quận/ huyện và có thể cả xã)

❑ Tiện ích: kit (EWARDS), web (D-MOSS), web + ứng dụng trên điện thoại (E-DENGUE)





- Wolbachia is a natural bacteria
- To be transmitted from mosquitoes to their offsprings via eggs
- Safety for human, animals, and environment
- To reduce disease transmission by mosquitoes (Dengue, Zika, Chikungunya)



Source: World Mosquito Program-WMP




Có bằng chứng ở mức độ toàn cầu về việc giảm tỷ lệ mắc bệnh sốt xuất huyết sau khi thực hiện thả muỗi mang wMel



Source: World Mosquito Program-WMP


Estimates of the effect of WMP's *Wolbachia* method on dengue incidence



* Yogyakarta data post-September 2020 excluded as releases in the control area commenced in Oct 2020



Có nhiều loại vắc xin phòng bệnh sốt xuất huyết đang được nghiên cứu và phát triển



*Based on current vaccine landscape (02/2023)



	CYD-TDV	TAK-003
Tuổi	9-45 tuổi <i>(Cần xét nghiệm huyết thanh học trước khi tiêm chủng)</i>	≥ 4 tuổi <i>(không bắt buộc xét nghiệm huyết thanh học trước khi tiêm)</i>
Số liều	3 liều (0, 6, 12 month)	2 liều (0, 3 month)
VE against VCD (xác nhận sự có mặt của vi rút Dengue)	65,6% (60,7-69,9)	62% (56,6-66,7)
VE against hospitalization VCD	80,8% (70,1-87,7)	83,6% (76,8-88,4)


Source:

Hadinegoro SR, *N Engl J Med* 2015; 373:1195-1206;

Rivera L, *Clin Infect Dis*, 2022 Aug 24;75(1):107-117



- Hướng tới tương lai bằng công cụ phòng ngừa mới hiệu quả hơn
 - Vắc xin
 - Kiểm soát véc tơ truyền bệnh:
 - Muỗi mang *Wolbachia*
 - Muỗi biến đôi gen



Thank you!

